Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade B 26.45 1.34% 0.35
ACAD closed down 4.11 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ACAD trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 1.34%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 1.34%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.34%
Mar 22 Inside Day Range Contraction 1.34%
Mar 21 20 DMA Support Bullish -2.83%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -2.83%
Mar 21 180 Bullish Setup Bullish Swing Setup -2.83%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.83%
Mar 21 Outside Day Range Expansion -2.83%
Mar 20 1,2,3 Pullback Bullish Bullish Swing Setup 0.88%

Older signals for ACAD ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Health Biopharmaceutical Pharmaceutical Industry Alpha Chemical Compounds Medication Alzheimer's Disease Schizophrenia Parkinson's Disease Glaucoma Neurological Disorders Chronic Pain Treatment Of Alzheimer's Disease Treatment Of Parkinson's Disease Treatment Of Glaucoma Allergan
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.12
52 Week Low 12.77
Average Volume 1,570,936
200-Day Moving Average 19.0086
50-Day Moving Average 23.6958
20-Day Moving Average 26.1485
10-Day Moving Average 26.674
Average True Range 1.1269
ADX 35.44
+DI 26.1865
-DI 12.609
Chandelier Exit (Long, 3 ATRs ) 24.7393
Chandelier Exit (Short, 3 ATRs ) 25.5107
Upper Bollinger Band 28.1395
Lower Bollinger Band 24.1575
Percent B (%b) 0.49
BandWidth 15.228407
MACD Line 0.9754
MACD Signal Line 1.1259
MACD Histogram -0.1505
Fundamentals Value
Market Cap 3.2 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -10.32
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.22
Resistance 3 (R3) 28.41 27.89 27.86
Resistance 2 (R2) 27.89 27.35 27.80 27.74
Resistance 1 (R1) 27.00 27.02 26.74 26.81 27.63
Pivot Point 26.48 26.48 26.36 26.39 26.48
Support 1 (S1) 25.59 25.94 25.33 25.40 24.57
Support 2 (S2) 25.07 25.61 24.98 24.46
Support 3 (S3) 24.18 25.07 24.34
Support 4 (S4) 23.99